1-2 of 2
Alexej Kuzmin
Close
Sort by
Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Marek Trneny, Thierry Lamy, MDPhD, Jan Walewski, MD PhD, David Belada, MD PhD, Jiri Mayer, John A Radford, MB ChB, MRCP, MD FRCP, Wojciech Jurczak, MD PhD, Franck Morschhauser, Julia Alexeeva, MD, Simon A. Rule, MD, Boris V Afanasyev, Professor, Kamil Kaplanov, Antoine Thyss, MD, Alexej Kuzmin, MD, Sergey Voloshin, MD, Kazimierz Kuliczkowski, prof., Agnieszka Giza, MD, Noel Milpied, MD PhD, Caterina Stelitano, MD, Reinhard Marks, MD, Lorenz Trümper, MD, Tsvetan Biyukov, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Luca Arcaini, MD
Journal: Blood
Blood (2016) 128 (22): 2978.
https://doi.org/10.1182/blood.V128.22.2978.2978
Published: 2016
Journal Articles

Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study

Valentin Goede, MD, Anja Engelke, MD, Kirsten Fischer, Javier Lopez Jimenez, Alexej Kuzmin, Martin JS Dyer, Katell Le Dû, Anna Marina Liberati, Rudolf Schlag, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, Günter Fingerle-Rowson, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 3327.
https://doi.org/10.1182/blood.V124.21.3327.3327
Published: 2014